Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1935-1940

  Azuma, K ^a   Ota, K ^b   Kawahara, A ^c   Hattori, S ^d   Iwama, E ^b   Harada, T ^b   Matsumoto, K ^b   Takayama, K ^b   Takamori, S ^a   Kage, M ^c   Hoshino, T ^a   Nakanishi, Y ^b,e   Okamoto, I ^e  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY HOSPITAL   (Japan)

^d KURUME UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

activating EGFR mutation; EGFR TKI; immunohistochemistry; nonsmall cell lung cancer; PD L1

Indexed keywords

CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84923072443     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu242     Document Type: Article

References (14)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics. CA Cancer J Clin 62 (2012), 10–29.
2. Oxnard, G.R., Binder, A., Janne, P.A., New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31 (2013), 1097–1104.
3. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
4. Topalian, S.L., Hodi, S.F., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
5. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
6. Kobayashi, S., Boqqon, T.J., Dayaram, T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005), 786–792.
7. Nagai, Y., Miyazawa, H., Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65 (2005), 7276–7282.
8. 2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium. Int Arch Allergy Immunol 160 (2013), 27–36.
9. Okabe, T., Okamoto, I., Tamura, K., et al. Differential constitutive activation of epidermal growth factor receptor in non small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67 (2007), 2046–2053.
10. Akbay, E.A., Koyama, S., Carretero, J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 12 (2013), 1355–1363.
11. Thompson, R.H., Kuntz, S.M., Leibovich, B.C., et al. Tumor B7-1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66 (2006), 3381–3385.
12. Hino, R., Kabashima, K., Kato, Y., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116 (2010), 1757–1766.
13. Nomi, T., Sho, M., Akahori, T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13 (2007), 2151–2157.
14. Hoos, A., Eggermont, A.M., Janetzki, S., et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102 (2010), 1388–1397.